Lupin: Inspection of Nagpur plant complete, no observation

Lupin Limited has announced the completion of the United States Food & Drug Administration (USFDA) inspection carried out at its Nagpur oral solid manufacturing facility. The inspection was carried out between August 5 to August 8, 2019. The inspection was successfully completed without any 483 observations.

The Nagpur facility is Lupin’s latest oral solid dosage facility and this was the sixth USFDA inspection at the facility.

Earlier this week, French National Agency for Medicines and Health Products Safety (ANSM) completed its inspection held between April 8-12, 2019. The inspection was of its finished product manufacturing facility (Unit-1) at Mandideep. No critical or major observations were recorded.

For the quarter ending June 2019, Lupin’s revenue grew by 15.4 per cent YoY to Rs. 4,355.8 crore. EBITDA during the quarter rose by 31.1 per cent to Rs. 932.5 crore. Whereas, the net profit jumped by 49.5 per cent to Rs. 303.1.

On Thursday, the stock of Lupin closed at Rs 761.20 per share, down by 2.6 per cent. During the day, it made intra-day high and low of Rs 791.40 and Rs 750.40, respectively.